Latest Publications

@article{rihova_transcription_2022,

title = {Transcription factor c-Myb: novel prognostic factor in osteosarcoma.},

author = {Kamila Říhová and Monika Dúcka and Iva Staniczková Zambo and Ladislava Vymětalová and Martin Šrámek and Filip Trčka and Jan Verner and Stanislav Drápela and Radek Fedr and Tereza Suchánková and Barbora Pavlatovská and Eva Ondroušková and Irena Kubelková and Danica Zapletalová and Štěpán Tuček and Peter Múdry and Dagmar Adámková Krákorová and Lucia Knopfová and Jan Šmarda and Karel Souček and Lubor Borsig and Petr Beneš},

doi = {10.1007/s10585-021-10145-4},

issn = {1573-7276 0262-0898},

year  = {2022},

date = {2022-04-01},

journal = {Clinical & experimental metastasis},

volume = {39},

number = {2},

pages = {375–390},

abstract = {The transcription factor c-Myb is an oncoprotein promoting cell proliferation and survival when aberrantly activated/expressed, thus contributing to malignant transformation. Overexpression of c-Myb has been found in leukemias, breast, colon and adenoid cystic carcinoma. Recent studies revealed its expression also in osteosarcoma cell lines and suggested its functional importance during bone development. However, the relevance of c-Myb in control of osteosarcoma progression remains unknown. A retrospective clinical study was carried out to assess a relationship between c-Myb expression in archival osteosarcoma tissues and prognosis in a cohort of high-grade osteosarcoma patients. In addition, MYB was depleted in metastatic osteosarcoma cell lines SAOS-2 LM5 and 143B and their growth, chemosensitivity, migration and metastatic activity were determined. Immunohistochemical analysis revealed that high c-Myb expression was significantly associated with poor overall survival in the cohort and metastatic progression in young patients. Increased level of c-Myb was detected in metastatic osteosarcoma cell lines and its depletion suppressed their growth, colony-forming capacity, migration and chemoresistance in vitro in a cell line-dependent manner. MYB knock-out resulted in reduced metastatic activity of both SAOS-2 LM5 and 143B cell lines in immunodeficient mice. Transcriptomic analysis revealed the c-Myb-driven functional programs enriched for genes involved in the regulation of cell growth, stress response, cell adhesion and cell differentiation/morphogenesis. Wnt signaling pathway was identified as c-Myb target in osteosarcoma cells. Taken together, we identified c-Myb as a negative prognostic factor in osteosarcoma and showed its involvement in the regulation of osteosarcoma cell growth, chemosensitivity, migration and metastatic activity.},

note = {Place: Netherlands},

keywords = {*Bone Neoplasms/pathology, *Osteosarcoma/pathology, Animals, c-Myb, Cell Line, Cell Movement/genetics, Cell Proliferation, Chemoresistance, Gene Expression Regulation, Humans, Metastasis, Mice, Neoplastic, Osteosarcoma, Prognosis, proliferation, Retrospective Studies, Tumor, Wnt Signaling Pathway},

pubstate = {published},

tppubtype = {article}

}

@article{krkoska_role_2022,

title = {Role of miR-653 and miR-29c in downregulation of CYP1A2 expression in hepatocellular carcinoma.},

author = {Martin Krkoška and Jana Nekvindová and Kateřina Nevědělová and Veronika Zubáňová and Lenka Radová and Jan Vondráček and Jarmila Herůdková and Ondřej Slabý and Igor Kiss and Lucia Bohovicová and Pavel Fabian and Zuzana Tylichová and Zdeněk Kala and Petr Kysela and Lenka Ostřížková and Vladimír Palička and Alena Hyršlová Vaculová},

doi = {10.1007/s43440-021-00338-9},

issn = {2299-5684 1734-1140},

year  = {2022},

date = {2022-02-01},

journal = {Pharmacological reports : PR},

volume = {74},

number = {1},

pages = {148–158},

abstract = {BACKGROUND: Hepatocellular carcinoma (HCC) is a major contributor to the worldwide cancer burden. Recent studies on HCC have demonstrated dramatic alterations in expression of several cytochrome P450 (CYP) family members that play a crucial role in biotransformation of many drugs and other xenobiotics; however, the mechanisms responsible for their deregulation remain unclear. METHODS: We investigated a potential involvement of miRNAs in downregulation of expression of CYPs observed in HCC tumors. We compared miRNA expression profiles (TaqMan Array Human MicroRNA v3.0 TLDA qPCR) between HCC human patient tumors with strong (CYP-) and weak/no (CYP+) downregulation of drug-metabolizing CYPs. The role of significantly deregulated miRNAs in modulation of expression of the CYPs and associated xenobiotic receptors was then investigated in human liver HepaRG cells transfected with relevant miRNA mimics or inhibitors. RESULTS: We identified five differentially expressed miRNAs in CYP- versus CYP+ tumors, namely miR-29c, miR-125b1, miR-505, miR-653 and miR-675. The two most-upregulated miRNAs found in CYP- tumor samples, miR-29c and miR-653, were found to act as efficient suppressors of CYP1A2 or AHR expression. CONCLUSIONS: Our results revealed a novel role of miR-653 and miR-29c in regulation of expresion of CYPs involved in crucial biotransformation processes in liver, which are often deregulated during liver cancer progression.},

note = {Place: Switzerland},

keywords = {*Carcinoma, *Liver Neoplasms/genetics/metabolism, AhR, Biotransformation, Cell Line, CYP1A2, Cytochrome P-450 CYP1A2/*metabolism, Down-Regulation, Gene Expression Regulation, Hepatocellular carcinoma, Hepatocellular/genetics/metabolism, Hepatocytes/metabolism, Humans, MicroRNA, MicroRNAs/*metabolism, Neoplastic, Tumor, Xenobiotics/metabolism},

pubstate = {published},

tppubtype = {article}

}

@article{krkoska_deregulation_2021,

title = {Deregulation of signaling pathways controlling cell survival and proliferation in cancer cells alters induction of cytochrome P450 family 1 enzymes.},

author = {Martin Krkoška and Jana Svobodová and Markéta Kabátková and Ondřej Zapletal and Alena Hyršlová Vaculová and Jana Nekvindová and Jan Vondráček},

doi = {10.1016/j.tox.2021.152897},

issn = {1879-3185 0300-483X},

year  = {2021},

date = {2021-09-01},

journal = {Toxicology},

volume = {461},

pages = {152897},

abstract = {Cytochrome P450 family 1 (CYP1) enzymes contribute both to metabolism of xenobiotics and to the control of endogenous levels of ligands of the aryl hydrocarbon receptor (AhR). Their activities, similar to other CYPs, can be altered in tumor tissues. Here, we examined a possible role of proliferative/survival pathways signaling, which is often deregulated in tumor cells, and possible links with p300 histone acetyltransferase (a transcriptional co-activator) in the control of CYP1 expression, focusing particularly on CYP1A1. Using cell models derived from human liver, we observed that the induction of CYP1A1 expression, as well as other CYP1 enzymes, was reduced in exponentially growing cells, as compared with their non-dividing counterparts. The siRNA-mediated inhibition of proliferation/pro-survival signaling pathway effectors (such as β-catenin and/or Hippo pathway effectors YAP/TAZ) increased the AhR ligand-induced CYP1A1 mRNA levels in liver HepaRG cells, and/or in colon carcinoma HCT-116 cells. The activation of proliferative Wnt/β-catenin signaling in HCT-116 cells reduced both the induction of CYP1 enzymes and the binding of p300 to the promoter of CYP1A1 or CYP1B1 genes. These results seem to indicate that aberrant proliferative signaling in tumor cells could suppress induction of CYP1A1 (or other CYP1 enzymes) via competition for p300 binding. This mechanism could be involved in modulation of the metabolism of both endogenous and exogenous substrates of CYP1A1 (and other CYP1 enzymes), with possible further consequences for alterations of the AhR signaling in tumor cells, or additional functional roles of CYP1 enzymes.},

note = {Place: Ireland},

keywords = {AhR, Cancer cells, Cell Line, Cell Proliferation, Cell Proliferation/*physiology, Cell Survival/physiology, Colonic Neoplasms/genetics/*pathology, CYP1 enzymes, Cytochrome P-450 CYP1A1/biosynthesis/*genetics, E1A-Associated p300 Protein/metabolism, Enzyme Induction/physiology, Gene Expression Regulation, HCT116 Cells, Hippo Signaling Pathway/physiology, Humans, Liver/*pathology, Neoplastic, p300, Signal Transduction/physiology, Tumor, Wnt Signaling Pathway/physiology, β-Catenin signaling},

pubstate = {published},

tppubtype = {article}

}

@article{mickova_skp2_2021,

title = {Skp2 and Slug Are Coexpressed in Aggressive Prostate Cancer and Inhibited by Neddylation Blockade.},

author = {Alena Mickova and Gvantsa Kharaishvili and Daniela Kurfurstova and Mariam Gachechiladze and Milan Kral and Ondrej Vacek and Barbora Pokryvkova and Martin Mistrik and Karel Soucek and Jan Bouchal},

doi = {10.3390/ijms22062844},

issn = {1422-0067},

year  = {2021},

date = {2021-03-01},

journal = {International journal of molecular sciences},

volume = {22},

number = {6},

abstract = {Prostate cancer (PCa) is the second leading cause of cancer-related deaths in men in Western countries, and there is still an urgent need for a better understanding of PCa progression to inspire new treatment strategies. Skp2 is a substrate-recruiting component of the E3 ubiquitin ligase complex, whose activity is regulated through neddylation. Slug is a transcriptional repressor involved in the epithelial-to-mesenchymal transition, which may contribute to therapy resistance. Although Skp2 has previously been associated with a mesenchymal phenotype and prostate cancer progression, the relationship with Slug deserves further elucidation. We have previously shown that a high Gleason score (≥8) is associated with higher Skp2 and lower E-cadherin expression. In this study, significantly increased expression of Skp2, AR, and Slug, along with E-cadherin downregulation, was observed in primary prostate cancer in patients who already had lymph node metastases. Skp2 was slightly correlated with Slug and AR in the whole cohort (Rs 0.32 and 0.37, respectively), which was enhanced for both proteins in patients with high Gleason scores (Rs 0.56 and 0.53, respectively) and, in the case of Slug, also in patients with metastasis to lymph nodes (Rs 0.56). Coexpression of Skp2 and Slug was confirmed in prostate cancer tissues by multiplex immunohistochemistry and confocal microscopy. The same relationship between these two proteins was observed in three sets of prostate epithelial cell lines (PC3, DU145, and E2) and their mesenchymal counterparts. Chemical inhibition of Skp2, but not RNA interference, modestly decreased Slug protein in PC3 and its docetaxel-resistant subline PC3 DR12. Importantly, chemical inhibition of Skp2 by MLN4924 upregulated p27 and decreased Slug expression in PC3, PC3 DR12, and LAPC4 cells. Novel treatment strategies targeting Skp2 and Slug by the neddylation blockade may be promising in advanced prostate cancer, as recently documented for other aggressive solid tumors.},

note = {Place: Switzerland},

keywords = {*Protein Processing, Androgen/genetics/metabolism, Antigens, Antineoplastic Agents/pharmacology, Cadherins/genetics/metabolism, CD/genetics/metabolism, Cell Line, Cell Survival/drug effects, Cyclin-Dependent Kinase Inhibitor p27/genetics/metabolism, Cyclopentanes/pharmacology, Docetaxel/pharmacology, Epithelial-Mesenchymal Transition/genetics, Gene Expression Regulation, Humans, Immunohistochemistry, Lymphatic Metastasis, Male, multiplex, NEDD8 Protein/*genetics/metabolism, neddylation, Neoplasm Grading, Neoplastic, PC-3 Cells, Post-Translational, Prostate cancer, Prostate/metabolism/pathology, Prostatic Neoplasms/*genetics/metabolism/pathology, Pyrimidines/pharmacology, Receptors, RNA, S-Phase Kinase-Associated Proteins/antagonists & inhibitors/*genetics/metabolism, Skp2 (S-phase kinase-associated protein 2), Slug, Small Interfering/genetics/metabolism, Snail Family Transcription Factors/*genetics/metabolism, Tumor},

pubstate = {published},

tppubtype = {article}

}

@article{remsik_tgf-_2020,

title = {TGF-β regulates Sca-1 expression and plasticity of pre-neoplastic mammary epithelial stem cells.},

author = {Ján Remšík and Markéta Pícková and Ondřej Vacek and Radek Fedr and Lucia Binó and Aleš Hampl and Karel Souček},

doi = {10.1038/s41598-020-67827-4},

issn = {2045-2322},

year  = {2020},

date = {2020-07-01},

journal = {Scientific reports},

volume = {10},

number = {1},

pages = {11396},

abstract = {The epithelial-mesenchymal plasticity, in tight association with stemness, contributes to the mammary gland homeostasis, evolution of early neoplastic lesions and cancer dissemination. Focused on cell surfaceome, we used mouse models of pre-neoplastic mammary epithelial and cancer stem cells to reveal the connection between cell surface markers and distinct cell phenotypes. We mechanistically dissected the TGF-β family-driven regulation of Sca-1, one of the most commonly used adult stem cell markers. We further provided evidence that TGF-β disrupts the lineage commitment and promotes the accumulation of tumor-initiating cells in pre-neoplastic cells.},

note = {Place: England},

keywords = {Animal/pathology, Animals, Ataxin-1/*metabolism, Breast Neoplasms/genetics/*pathology, Cell Line, Cell Plasticity/genetics, Epithelial Cells/pathology, Epithelial-Mesenchymal Transition/genetics, ErbB-2/genetics, Experimental/genetics/*pathology, Female, Gene Expression Regulation, Humans, Mammary Glands, Mammary Neoplasms, Mice, Neoplastic, Neoplastic Stem Cells/*pathology, Receptor, Recombinant Proteins/genetics/metabolism, Signal Transduction/genetics, Transforming Growth Factor beta/genetics/*metabolism, Tumor/transplantation},

pubstate = {published},

tppubtype = {article}

}

@article{boudny_novel_2019,

title = {Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.},

author = {Miroslav Boudny and Jana Zemanova and Prashant Khirsariya and Marek Borsky and Jan Verner and Jana Cerna and Alexandra Oltova and Vaclav Seda and Marek Mraz and Josef Jaros and Zuzana Jaskova and Michaela Spunarova and Yvona Brychtova and Karel Soucek and Stanislav Drapela and Marie Kasparkova and Jiri Mayer and Kamil Paruch and Martin Trbusek},

doi = {10.3324/haematol.2018.203430},

issn = {1592-8721 0390-6078},

year  = {2019},

date = {2019-12-01},

journal = {Haematologica},

volume = {104},

number = {12},

pages = {2443–2455},

abstract = {Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation, and cases with TP53 defects more frequently experience early progression of the disease. Development of alternative therapeutic approaches is, therefore, of critical importance. Here we report details of the anti-chronic lymphocytic leukemia single-agent activity of MU380, our recently identified potent, selective, and metabolically robust inhibitor of checkpoint kinase 1. We also describe a newly developed enantioselective synthesis of MU380, which allows preparation of gram quantities of the substance. Checkpoint kinase 1 is a master regulator of replication operating primarily in intra-S and G(2)/M cell cycle checkpoints. Initially tested in leukemia and lymphoma cell lines, MU380 significantly potentiated efficacy of gemcitabine, a clinically used inducer of replication stress. Moreover, MU380 manifested substantial single-agent activity in both TP53-wild type and TP53-mutated leukemia and lymphoma cell lines. In chronic lymphocytic leukemia-derived cell lines MEC-1, MEC-2 (both TP53-mut), and OSU-CLL (TP53-wt) the inhibitor impaired cell cycle progression and induced apoptosis. In primary clinical samples, MU380 used as a single-agent noticeably reduced the viability of unstimulated chronic lymphocytic leukemia cells as well as those induced to proliferate by anti-CD40/IL-4 stimuli. In both cases, effects were comparable in samples harboring p53 pathway dysfunction (TP53 mutations or ATM mutations) and TP53-wt/ATM-wt cells. Lastly, MU380 also exhibited significant in vivo activity in a xenotransplant mouse model (immunodeficient strain NOD-scid IL2Rγ(null) ) where it efficiently suppressed growth of subcutaneous tumors generated from MEC-1 cells.},

note = {Place: Italy},

keywords = {*Drug Synergism, *Mutation, Animals, Antimetabolites, Antineoplastic/pharmacology, Apoptosis, B-Cell/*drug therapy/genetics/pathology, Biomarkers, Cell Cycle, Cell Proliferation, Checkpoint Kinase 1/*antagonists & inhibitors, Chronic, Cultured, Deoxycytidine/analogs & derivatives/pharmacology, Drug resistance, Female, gemcitabine, Gene Expression Regulation, Humans, Inbred NOD, Leukemia, Lymphocytic, Mice, Neoplasm/drug effects, Neoplastic/*drug effects, Piperidines/*pharmacology, Protein Kinase Inhibitors/pharmacology, Pyrazoles/*pharmacology, Pyrimidines/*pharmacology, SCID, Tumor Cells, Tumor Suppressor Protein p53/*genetics, Tumor/genetics, Xenograft Model Antitumor Assays},

pubstate = {published},

tppubtype = {article}

}

@article{soucek_presence_2018,

title = {Presence of growth/differentiation factor-15 cytokine in human follicular fluid, granulosa cells, and oocytes.},

author = {Karel Souček and Alice Malenovská and Zuzana Kahounová and Ján Remšík and Zuzana Holubcová and Tomáš Soukup and Daniela Kurfürstová and Jan Bouchal and Tereza Suchánková and Eva Slabáková and Aleš Hampl},

doi = {10.1007/s10815-018-1230-5},

issn = {1573-7330 1058-0468},

year  = {2018},

date = {2018-08-01},

journal = {Journal of assisted reproduction and genetics},

volume = {35},

number = {8},

pages = {1407–1417},

abstract = {PURPOSE: The purpose of the study was to determine whether the GDF-15 is present in follicular fluid; to evaluate if there is a relation between follicular and serum levels of GDF-15 and fertility status of study subjects; and to test whether granulosa cells, oocytes, or both produce GDF-15. METHODS: This study used follicular fluid (FF, serum, and oocytes obtained under informed consent from women undergoing oocyte retrieval for in vitro fertilization. It also used ovaries from deceased preterm newborns. Collection of FF and blood at the time of oocyte retrieval, ELISA and western blot were performed to determine levels and forms of GDF-15. Concentrations of GDF-15 in FF and serum, its expression in ovarian tissue, and secretion from granulosa cells were analyzed. RESULTS: GDF-15 concentration in FF ranged from 35 to 572 ng/ml, as determined by ELISA. Western blot analysis revealed the GDF-15 pro-dimer only in FF. Both normal healthy and cancerous granulosa cells secreted GDF-15 into culture media. Primary oocytes displayed cytoplasmic GDF-15 positivity in immunostained newborn ovaries, and its expression was also observed in fully grown human oocytes. CONCLUSIONS: To the best of our knowledge, this is the first documentation of cytokine GDF-15 presence in follicular fluid. Its concentration was not associated with donor/patient fertility status. Our data also show that GDF-15 is expressed and inducible in both normal healthy and cancerous granulosa cells, as well as in oocytes.},

note = {Place: Netherlands},

keywords = {Adult, Cell Differentiation/*genetics, Developmental, Female, Fertilization in Vitro, Follicular fluid, Follicular Fluid/*metabolism, Follicular granulosa cells, Gene Expression Regulation, Granulosa Cells/*metabolism, Growth Differentiation Factor 15/*genetics/isolation & purification, Growth/differentiation factor-15, Humans, IVF, Oocyte Retrieval, Oocytes/metabolism},

pubstate = {published},

tppubtype = {article}

}

@article{prochazkova_adaptive_2018,

title = {Adaptive changes in global gene expression profile of lung carcinoma A549 cells acutely exposed to distinct types of AhR ligands.},

author = {Jiřina Procházková and Simona Strapáčová and Lucie Svržková and Zdeněk Andrysík and Martina Hýžďalová and Eva Hrubá and Kateřina Pěnčíková and Helena Líbalová and Jan Topinka and Jiří Kléma and Joaquín M. Espinosa and Jan Vondráček and Miroslav Machala},

doi = {10.1016/j.toxlet.2018.04.024},

issn = {1879-3169 0378-4274},

year  = {2018},

date = {2018-08-01},

journal = {Toxicology letters},

volume = {292},

pages = {162–174},

abstract = {Exposure to persistent ligands of aryl hydrocarbon receptor (AhR) has been found to cause lung cancer in experimental animals, and lung adenocarcinomas are often associated with enhanced AhR expression and aberrant AhR activation. In order to better understand the action of toxic AhR ligands in lung epithelial cells, we performed global gene expression profiling and analyze TCDD-induced changes in A549 transcriptome, both sensitive and non-sensitive to CH223191 co-treatment. Comparison of our data with results from previously reported microarray and ChIP-seq experiments enabled us to identify candidate genes, which expression status reflects exposure of lung cancer cells to TCDD, and to predict processes, pathways (e.g. ER stress, Wnt/β-cat, IFNɣ, EGFR/Erbb1), putative TFs (e.g. STAT, AP1, E2F1, TCF4), which may be implicated in adaptive response of lung cells to TCDD-induced AhR activation. Importantly, TCDD-like expression fingerprint of selected genes was observed also in A549 cells exposed acutely to both toxic (benzo[a]pyrene, benzo[k]fluoranthene) and endogenous AhR ligands (2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid methyl ester and 6-formylindolo[3,2-b]carbazole). Overall, our results suggest novel cellular candidates, which could help to improve monitoring of AhR-dependent transcriptional activity during acute exposure of lung cells to distinct types of environmental pollutants.},

note = {Place: Netherlands},

keywords = {A549 Cells, Aryl hydrocarbon receptor, Aryl Hydrocarbon/*agonists/metabolism, Azo Compounds/toxicity, Basic Helix-Loop-Helix Transcription Factors/*agonists/metabolism, Benzo(a)pyrene/toxicity, Carbazoles/toxicity, Dioxins, Environmental Pollutants/*toxicity, Fluorenes/toxicity, Gene Expression Profiling/methods, Gene Expression Regulation, Gene Regulatory Networks/drug effects, Genetic/drug effects, Global gene expression profiling, Humans, Indoles/toxicity, Ligands, Lung cancer, Lung Neoplasms/*genetics/metabolism, Neoplastic/*drug effects, Oligonucleotide Array Sequence Analysis, Polychlorinated Dibenzodioxins/toxicity, Pyrazoles/toxicity, Receptors, Signal Transduction/drug effects, Thiazoles/toxicity, Time Factors, Transcription, Transcriptional Activation/drug effects, Transcriptome/*drug effects},

pubstate = {published},

tppubtype = {article}

}

@article{paculova_brca1_2017,

title = {BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.},

author = {Hana Paculová and Juraj Kramara and Šárka Šimečková and Radek Fedr and Karel Souček and Ondřej Hylse and Kamil Paruch and Marek Svoboda and Martin Mistrík and Jiří Kohoutek},

doi = {10.1177/1010428317727479},

issn = {1423-0380 1010-4283},

year  = {2017},

date = {2017-10-01},

journal = {Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine},

volume = {39},

number = {10},

pages = {1010428317727479},

abstract = {A broad spectrum of tumors develop resistance to classic chemotherapy, necessitating the discovery of new therapies. One successful strategy exploits the synthetic lethality between poly(ADP-ribose) polymerase 1/2 proteins and DNA damage response genes, including BRCA1, a factor involved in homologous recombination-mediated DNA repair, and CDK12, a transcriptional kinase known to regulate the expression of DDR genes. CHK1 inhibitors have been shown to enhance the anti-cancer effect of DNA-damaging compounds. Since loss of BRCA1 increases replication stress and leads to DNA damage, we tested a hypothesis that CDK12- or BRCA1-depleted cells rely extensively on S-phase-related CHK1 functions for survival. The silencing of BRCA1 or CDK12 sensitized tumor cells to CHK1 inhibitors in vitro and in vivo. BRCA1 downregulation combined with CHK1 inhibition induced excessive amounts of DNA damage, resulting in an inability to complete the S-phase. Therefore, we suggest CHK1 inhibition as a strategy for targeting BRCA1- or CDK12-deficient tumors.},

note = {Place: Netherlands},

keywords = {Animals, BRCA1, BRCA1 Protein/antagonists & inhibitors/*genetics, CDK12, Checkpoint Kinase 1/*genetics, CHK1 inhibitor, Colorectal Neoplasms/drug therapy/*genetics/pathology, Cyclin-Dependent Kinases/antagonists & inhibitors/*genetics, DNA damage response, DNA Damage/drug effects, Drug resistance, Gene Expression Regulation, Gene Silencing, HCT116 Cells, Humans, Mice, Neoplasm/genetics, Neoplastic/drug effects, Poly (ADP-Ribose) Polymerase-1/genetics, Pyrazoles/administration & dosage, Pyrimidines/administration & dosage, Transcription, Xenograft Model Antitumor Assays},

pubstate = {published},

tppubtype = {article}

}

@article{slabakova_alternative_2017,

title = {Alternative mechanisms of miR-34a regulation in cancer.},

author = {Eva Slabáková and Zoran Culig and Ján Remšík and Karel Souček},

doi = {10.1038/cddis.2017.495},

issn = {2041-4889},

year  = {2017},

date = {2017-10-01},

journal = {Cell death & disease},

volume = {8},

number = {10},

pages = {e3100},

abstract = {MicroRNA miR-34a is recognized as a master regulator of tumor suppression. The strategy of miR-34a replacement has been investigated in clinical trials as the first attempt of miRNA application in cancer treatment. However, emerging outcomes promote the re-evaluation of existing knowledge and urge the need for better understanding the complex biological role of miR-34a. The targets of miR-34a encompass numerous regulators of cancer cell proliferation, survival and resistance to therapy. MiR-34a expression is transcriptionally controlled by p53, a crucial tumor suppressor pathway, often disrupted in cancer. Moreover, miR-34a abundance is fine-tuned by context-dependent feedback loops. The function and effects of exogenously delivered or re-expressed miR-34a on the background of defective p53 therefore remain prominent issues in miR-34a based therapy. In this work, we review p53-independent mechanisms regulating the expression of miR-34a. Aside from molecules directly interacting with MIR34A promoter, processes affecting epigenetic regulation and miRNA maturation are discussed. Multiple mechanisms operate in the context of cancer-associated phenomena, such as aberrant oncogene signaling, EMT or inflammation. Since p53-dependent tumor-suppressive mechanisms are disturbed in a substantial proportion of malignancies, we summarize the effects of miR-34a modulation in cell and animal models in the clinically relevant context of disrupted or insufficient p53 function.},

note = {Place: England},

keywords = {*Genes, Animals, Epigenesis, Epithelial-Mesenchymal Transition/genetics, Gene Expression Regulation, Genetic/genetics, Humans, MicroRNAs/*genetics, Neoplasms/*genetics/*pathology, Neoplastic/genetics, Promoter Regions, Tumor Suppressor, Tumor Suppressor Protein p53/*genetics},

pubstate = {published},

tppubtype = {article}

}

@article{kabatkova_inhibition_2015,

title = {Inhibition of β-catenin signalling promotes DNA damage elicited by benzo[a]pyrene in a model of human colon cancer cells via CYP1 deregulation.},

author = {Markéta Kabátková and Ondřej Zapletal and Zuzana Tylichová and Jiří Neča and Miroslav Machala and Alena Milcová and Jan Topinka and Alois Kozubík and Jan Vondráček},

doi = {10.1093/mutage/gev019},

issn = {1464-3804 0267-8357},

year  = {2015},

date = {2015-07-01},

journal = {Mutagenesis},

volume = {30},

number = {4},

pages = {565–576},

abstract = {Deregulation of Wnt/β-catenin signalling plays an important role in the pathogenesis of colorectal cancer. Interestingly, this pathway has been recently implicated in transcriptional control of cytochrome P450 (CYP) family 1 enzymes, which are responsible for bioactivation of a number of dietary carcinogens. In the present study, we investigated the impact of inhibition of Wnt/β-catenin pathway on metabolism and genotoxicity of benzo[a]pyrene (BaP), a highly mutagenic polycyclic aromatic hydrocarbon and an efficient ligand of the aryl hydrocarbon receptor, which is known as a primary regulator of CYP1 expression, in cellular models derived from colorectal tumours. We observed that a synthetic inhibitor of β-catenin, JW74, significantly increased formation of BaP-induced DNA adducts in both colorectal adenoma and carcinoma-derived cell lines. Using the short interfering RNA (siRNA) targeting β-catenin, we then found that β-catenin knockdown in HCT116 colon carcinoma cells significantly enhanced formation of covalent DNA adducts by BaP and histone H2AX phosphorylation, as detected by (32)P-postlabelling technique and immunocytochemistry, respectively, and it also induced expression of DNA damage response genes, such as CDKN1A or DDB2. The increased formation of DNA adducts formed by BaP upon β-catenin knockdown corresponded with enhanced production of major BaP metabolites, as well as with an increased expression/activity of CYP1 enzymes. Finally, using siRNA-mediated knockdown of CYP1A1, we confirmed that this enzyme plays a major role in formation of BaP-induced DNA adducts in HCT116 cells. Taken together, the present results indicated that the siRNA-mediated inhibition of β-catenin signalling, which is aberrantly activated in a majority of colorectal cancers, modulated genotoxicity of dietary carcinogen BaP in colon cell model in vitro, via a mechanism involving up-regulation of CYP1 expression and activity.},

note = {Place: England},

keywords = {*DNA Damage, Apoptosis, Aryl Hydrocarbon/genetics/metabolism, Benzo(a)pyrene/*adverse effects, beta Catenin/*antagonists & inhibitors/genetics/metabolism, Blotting, Carcinogens, Cell Proliferation, Colonic Neoplasms/drug therapy/*etiology/*pathology, Cultured, Cytochrome P-450 CYP1A1/antagonists & inhibitors/genetics/*metabolism, DNA Adducts/*adverse effects, Environmental/adverse effects, Enzymologic/*drug effects, Gene Expression Regulation, Humans, Immunoenzyme Techniques, Messenger/genetics, Neoplastic/*drug effects, Real-Time Polymerase Chain Reaction, Receptors, Reverse Transcriptase Polymerase Chain Reaction, RNA, Small Interfering/genetics, Tumor Cells, Western},

pubstate = {published},

tppubtype = {article}

}

@article{libalova_analysis_2014,

title = {Analysis of gene expression changes in A549 cells induced by organic compounds from respirable air particles.},

author = {Helena Líbalová and Simona Krčková and Kateřina Uhlířová and Jiří Kléma and Miroslav Ciganek and Pavel Jr Rössner and Radim J. Šrám and Jan Vondráček and Miroslav Machala and Jan Topinka},

doi = {10.1016/j.mrfmmm.2014.10.002},

issn = {1873-135X 0027-5107},

year  = {2014},

date = {2014-12-01},

journal = {Mutation research},

volume = {770},

pages = {94–105},

abstract = {A number of toxic effects of respirable ambient air particles (genotoxic effects, inflammation, oxidative damage) have been attributed to organic compounds bound onto the particle surface. In this study, we analyzed global gene expression changes caused by the extractable organic matters (EOMs) from respirable airborne particles <2.5μm (PM2.5), collected at 3 localities from heavily polluted areas of the Czech Republic and a control locality with low pollution levels, in human lung epithelial A549 cells. Although the sampled localities differed in both extent and sources of air pollution, EOMs did not induce substantially different gene expression profiles. The number of transcripts deregulated in A549 cells treated with the lowest EOM concentration (10μg/ml) ranged from 65 to 85 in 4 sampling localities compared to the number of transcripts deregulated after 30μg/ml and 60μg/ml of EOMs, which ranged from 90 to 109, and from 149 to 452, respectively. We found numerous commonly deregulated genes and pathways related to activation of the aryl hydrocarbon receptor (AhR) and metabolism of xenobiotics and endogenous compounds. We further identified deregulation of expression of the genes involved in pro-inflammatory processes, oxidative stress response and in cancer and developmental pathways, such as TGF-β and Wnt signaling pathways. No cell cycle arrest, DNA repair or pro-apoptotic responses were identified at the transcriptional level after the treatment of A549 cells with EOMs. In conclusion, numerous processes and pathways deregulated in response to EOMs suggest a significant role of activated AhR. Interestingly, we did not observe substantial gene expression changes related to DNA damage response, possibly due to the antagonistic effect of non-genotoxic EOM components. Moreover, a comparison of EOM effects with other available data on modulation of global gene expression suggests possible overlap among the effects of PM2.5, EOMs and various types of AhR agonists.},

note = {Place: Netherlands},

keywords = {A549 Cells, Adenocarcinoma of Lung, Adenocarcinoma/genetics/pathology, Ah receptor, Cultured, gene expression profile, Gene Expression Profiling, Gene Expression Regulation, Gene Expression/*drug effects, Humans, Lung Neoplasms/genetics/pathology, Microarray Analysis, Neoplastic/drug effects, Organic Chemicals/*pharmacology, PAHs, Particulate Matter/*pharmacology, PM2.5, Respiratory Mucosa/drug effects/metabolism, Signal Transduction/drug effects/genetics, Tumor Cells},

pubstate = {published},

tppubtype = {article}

}

@article{smerdova_upregulation_2014,

title = {Upregulation of CYP1B1 expression by inflammatory cytokines is mediated by the p38 MAP kinase signal transduction pathway.},

author = {Lenka Smerdová and Jana Šmerdová and Markéta Kabátková and Jiří Kohoutek and Dalibor Blažek and Miroslav Machala and Jan Vondráček},

doi = {10.1093/carcin/bgu190},

issn = {1460-2180 0143-3334},

year  = {2014},

date = {2014-11-01},

journal = {Carcinogenesis},

volume = {35},

number = {11},

pages = {2534–2543},

abstract = {Cytochrome P450 1B1 (CYP1B1) is an enzyme that has a unique tumor-specific pattern of expression and is capable of bioactivating a wide range of carcinogenic compounds. We have reported previously that coordinated upregulation of CYP1B1 by inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and the aryl hydrocarbon receptor ligands, may increase bioactivation of promutagens, such as benzo[a]pyrene (BaP) in epithelial cells. Here, we extend those studies by describing a novel mechanism participating in the regulation of CYP1B1 expression, which involves activation of the p38 mitogen-activated protein kinase (p38) and mitogen- and stress-activated protein kinase 1 (MSK1). Using inhibitors of p38 and MSKs, as well as mouse embryonic cells derived from p38α-deficient and MSK1/2 double knockout mice, we show here that TNF-α potentiates CYP1B1 upregulation via the p38/MSK1 kinase cascade. Effects of this inflammatory cytokine on CYP1B1 expression further involve the positive transcription elongation factor b (P-TEFb). The inhibition of the P-TEFb subunit, cyclin-dependent kinase 9 (CDK9), which phosphorylates RNA polymerase II (RNAPII), prevented the enhanced CYP1B1 induction by a combination of BaP and inflammatory cytokine. Furthermore, using chromatin immunoprecipitation assays, we found that cotreatment of epithelial cells with TNF-α and BaP resulted in enhanced recruitment of both CDK9 and RNAPII to the Cyp1b1 gene promoter. Overall, these results have implications concerning the contribution of inflammatory factors to carcinogenesis, since enhanced CYP1B1 induction during inflammation may alter metabolism of exogenous carcinogens, as well as endogenous CYP1B1 substrates playing role in tumor development.},

note = {Place: England},

keywords = {Animals, Carcinogenesis/drug effects/*genetics, Carcinogens/toxicity, Cyclin-Dependent Kinase 9/genetics, Cytochrome P-450 CYP1B1/*biosynthesis/genetics, Cytokines/metabolism, Gene Expression Regulation, Humans, Mice, Neoplasms/chemically induced/*genetics/pathology, Neoplastic/drug effects, p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors/*genetics/metabolism, Positive Transcriptional Elongation Factor B/genetics, RNA Polymerase II/genetics, Signal Transduction/drug effects, Tumor Necrosis Factor-alpha/metabolism},

pubstate = {published},

tppubtype = {article}

}

@article{hruba_gene_2011,

title = {Gene expression changes in human prostate carcinoma cells exposed to genotoxic and nongenotoxic aryl hydrocarbon receptor ligands.},

author = {Eva Hrubá and Jan Vondráček and Helena Líbalová and Jan Topinka and Vítězslav Bryja and Karel Souček and Miroslav Machala},

doi = {10.1016/j.toxlet.2011.07.011},

issn = {1879-3169 0378-4274},

year  = {2011},

date = {2011-10-01},

journal = {Toxicology letters},

volume = {206},

number = {2},

pages = {178–188},

abstract = {Carcinogenic polycyclic aromatic hydrocarbons (PAHs) are known as efficient mutagens and ligands of the aryl hydrocarbon receptor (AhR), which has been suggested to play an important role in prostate carcinogenesis. In order to evaluate the complex relationship between the genotoxicity and the AhR-mediated activity of PAHs in prostate cells, we selected benzo[a]pyrene (BaP) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), as model genotoxic and nongenotoxic AhR ligands, respectively, to explore global changes in gene expression in LNCaP cells by microarray analysis. We identified 112 genes that were differentially expressed in cells treated for 24h with BaP, TCDD or both compounds. Our data indicated that the impacts of BaP and TCDD on transcriptome of LNCaP cells significantly overlap, since over 64% of significantly up-regulated genes and 47% of down-regulated genes were similarly affected by both AhR ligands. This suggested that the activation of AhR played a prominent role in the nongenotoxic effects of BaP in the prostate carcinoma cell model LNCaP. Both AhR ligands suppressed expression of genes associated with cell cycle progression, DNA replication, spindle assembly checkpoint or DNA repair, which probably occurred secondary to inhibition of cell cycle progression. In contrast, we identified Wnt5a, an important regulator of prostate cancer progression, to be induced as early as 6h after exposure to both AhR ligands. The AhR ligand-induced Wnt5a upregulation, together with other observed alterations of gene expression, may further contribute to enhanced cell plasticity of prostate carcinoma cells.},

note = {Place: Netherlands},

keywords = {Aryl Hydrocarbon/*agonists, Benzo(a)pyrene/*toxicity, Carcinogens, Carcinoma/metabolism, Cell Cycle/drug effects, Cell Line, DNA Repair/drug effects, DNA Replication/drug effects, Environmental/*toxicity, Gene Expression Profiling, Gene Expression Regulation, Humans, Ligands, Male, Mutagens/*toxicity, Neoplastic/*drug effects, Oligonucleotide Array Sequence Analysis, Polychlorinated Dibenzodioxins/*toxicity, Prostatic Neoplasms/*metabolism, Proto-Oncogene Proteins/genetics/metabolism, Receptors, Spindle Apparatus/drug effects, Time Factors, Tumor, Wnt Proteins/genetics/metabolism, Wnt-5a Protein},

pubstate = {published},

tppubtype = {article}

}

@article{vondracek_interactions_2011,

title = {Interactions of the aryl hydrocarbon receptor with inflammatory mediators: beyond CYP1A regulation.},

author = {Jan Vondrácek and Lenka Umannová and Miroslav Machala},

doi = {10.2174/138920011795016827},

issn = {1875-5453 1389-2002},

year  = {2011},

date = {2011-02-01},

journal = {Current drug metabolism},

volume = {12},

number = {2},

pages = {89–103},

abstract = {The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor, which plays a major role in toxic effects of environmental pollutants. It is a pivotal regulator of several xenobiotic-metabolizing enzymes (XMEs), and is now considered to play an important role also in control of cell cycle, apoptosis and cell differentiation. The accumulating evidence suggests that there exists a multiple crosstalk between AhR activation and the signaling pathways activated by inflammatory mediators, such as nuclear factor-κB, a pleiotropic transcription factor controlling the immune/inflammatory responses. In this review, we summarize the current knowledge about the interactions of AhR with inflammatory mediators leading to deregulation of the AhR-dependent XMEs, as well as the evidence pointing to the role of AhR in modulation of inflammatory signals. These include altered expression of proinflammatory cytokines, such as tumor necrosis factor-alpha or interleukin-6, and deregulation of expression/activity of principle enzymes producing inflammatory mediators, such as cyclooxygenase-2. Recent studies also indicate that various classes of AhR ligands may differentially modulate AhR-dependent toxic responses and inflammation, which opens an interesting opportunity for a targeted synthesis of AhR ligands with anti-inflammatory properties. Although the role of activated AhR in the regulation of inflammation is still far from being completely understood, the close interactions between AhR and inflammatory signaling evidently can play a significant role in immune dysfunctions, metabolism of xenobiotics or carcinogenesis. The current review will focus mostly on the interaction of AhR and inflammation relative to mechanisms associated with the pathology of carcinogenesis.},

note = {Place: Netherlands},

keywords = {Animals, Anti-Inflammatory Agents/pharmacology, Aryl Hydrocarbon Hydroxylases/*genetics/metabolism/*physiology, Aryl Hydrocarbon/drug effects/*physiology, Enzymologic/*physiology, Gene Expression Regulation, Humans, Inflammation Mediators/metabolism/*physiology, Inflammation/drug therapy/metabolism/physiopathology, Receptors, Signal Transduction/*physiology, Xenobiotics/metabolism},

pubstate = {published},

tppubtype = {article}

}

@article{hruba_genotoxic_2010,

title = {Genotoxic polycyclic aromatic hydrocarbons fail to induce the p53-dependent DNA damage response, apoptosis or cell-cycle arrest in human prostate carcinoma LNCaP cells.},

author = {Eva Hrubá and Lenka Trilecová and Sona Marvanová and Pavel Krcmár and Lenka Vykopalová and Alena Milcová and Helena Líbalová and Jan Topinka and Andrea Starsíchová and Karel Soucek and Jan Vondrácek and Miroslav Machala},

doi = {10.1016/j.toxlet.2010.06.004},

issn = {1879-3169 0378-4274},

year  = {2010},

date = {2010-09-01},

journal = {Toxicology letters},

volume = {197},

number = {3},

pages = {227–235},

abstract = {Exposure to polycyclic aromatic hydrocarbons (PAHs) has been positively associated with prostate cancer, but knowledge of the formation of PAH-DNA adducts and related genotoxic events in prostatic cells is limited. In the present study, benzo[a]pyrene (BaP), a potent mutagenic PAH, formed significant levels of DNA adducts in cell lines derived from human prostate carcinoma. When analyzing the effect of BaP on the induction of CYP1 enzymes participating in the metabolic activation of PAHs in LNCaP cells, we found that BaP induced expression of CYP1A1 and CYP1A2, but not CYP1B1 enzyme. Despite a significant amount of DNA adducts being formed by BaP and, to a lesser extent also by another strong genotoxin, dibenzo[a,l]pyrene, neither apoptosis nor cell-cycle arrest were induced in LNCaP cells. LNCaP cells were not sensitized to the induction of apoptosis by PAHs even through inhibition of the phosphoinositide-3-kinase/Akt pro-survival pathway. The lack of apoptosis was not due a disruption of expression of pro-apoptotic and pro-survival members of the Bcl-2 family of apoptosis regulators. In contrast to other genotoxic stimuli, genotoxic PAHs failed to induce DNA double-strand breaks, as illustrated by the lack of phosphorylation of histone H2AX or checkpoint kinase-2. BaP did not activate p53, as evidenced by the lack of p53 accumulation, phosphorylation at Ser15, or induction of p53 transcriptional targets. Taken together, although genotoxic PAHs produced significant levels of DNA adducts in a model of human prostate carcinoma cells, they did not activate the mechanisms leading to elimination of cells with significant damage to DNA, presumably due to their failure to activate the p53-dependent DNA damage response.},

note = {Place: Netherlands},

keywords = {Animals, Apoptosis/*drug effects, Carcinoma/*metabolism, Cell Line, DNA Damage/*drug effects, Environmental Pollutants/toxicity, Gene Expression Regulation, Male, Neoplastic/drug effects, Polycyclic Aromatic Hydrocarbons/*toxicity, Prostatic Neoplasms/*metabolism, Tumor, Tumor Suppressor Protein p53/*metabolism},

pubstate = {published},

tppubtype = {article}

}

@article{vondracek_role_2009,

title = {The role of aryl hydrocarbon receptor in regulation of enzymes involved in metabolic activation of polycyclic aromatic hydrocarbons in a model of rat liver progenitor cells.},

author = {Jan Vondrácek and Pavel Krcmár and Jirina Procházková and Lenka Trilecová and Martina Gavelová and Lenka Skálová and Barbora Szotáková and Martin Buncek and Hana Radilová and Alois Kozubík and Miroslav Machala},

doi = {10.1016/j.cbi.2009.03.011},

issn = {1872-7786 0009-2797},

year  = {2009},

date = {2009-07-01},

journal = {Chemico-biological interactions},

volume = {180},

number = {2},

pages = {226–237},

abstract = {In contrast to hepatocytes, there is only limited information about the expression and activities of enzymes participating in metabolic activation of environmental mutagens, including polycyclic aromatic hydrocarbons (PAHs), in liver progenitor cells. In rat liver "stem-like" WB-F344 cell line, sharing many characteristics with rat liver progenitor cells, PAHs are efficiently activated to their ultimate genotoxic metabolites forming DNA adducts. The present study aimed to characterize expression/activities of enzymes of two major pathways involved in the metabolism of benzo[a]pyrene (BaP): cytochrome P450 (CYP) family 1 enzymes and cytosolic aldo-keto reductases (AKRs). We report here that, apart from induction of CYP1A1 and CYP1B1 expression and the corresponding enzymatic activity, both BaP and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induced rat 3alpha-hydroxysteroid dehydrogenase (AKR1C9) expression and activity. In contrast, the aldehyde reductase AKR1A1 was not induced by either treatment. Thus, both CYP1 and AKR metabolic pathways were inducible in the model of liver progenitor cells. BaP and TCDD were efficient inducers of NAD(P)H:quinone oxidoreductase 1 (NQO1) expression and activity in WB-F344 cells, a principal enzyme of cellular antioxidant defense. Both compounds also induced expression of transcription factor NRF2, involved in control of enzymes protecting cells from oxidative stress. However, although BaP induced a significant formation of reactive oxygen species, it did not induce expression of heme oxygenase-1, suggesting that induction of oxidative stress by BaP was limited. Using shRNA against the aryl hydrocarbon receptor (AhR), we found that similar to CYP1A1 and CYP1B1, the AKR1C9 induction was AhR-dependent. Moreover, constitutive AKR1C9 levels in AhR-deficient rat BP8 hepatoma cells were significantly lower than in their AhR-positive 5L variant, thus supporting possible role of AhR in regulation of AKR1C9 expression. Taken together, both CYP1 and AKR1C9 appear to be AhR-regulated metabolic pathways, which may contribute to formation of pro-carcinogenic PAH metabolites in liver progenitor cells.},

note = {Place: Ireland},

keywords = {Animals, Aryl Hydrocarbon/*metabolism, Benzo(a)pyrene/toxicity, Cell Line, Dimethyl Sulfoxide/toxicity, Enzymologic/drug effects, Gene Expression Regulation, Gene Silencing, Hydrogen Peroxide/toxicity, Liver/*cytology/*enzymology, Polychlorinated Dibenzodioxins/analogs & derivatives/toxicity, Polycyclic Aromatic Hydrocarbons/*metabolism, Rats, Reactive Oxygen Species, Receptors, Stem Cells/*drug effects/*metabolism},

pubstate = {published},

tppubtype = {article}

}

@article{ondrouskova_heavy_2009,

title = {Heavy metals induce phosphorylation of the Bcl-2 protein by Jun N-terminal kinase.},

author = {Eva Ondrousková and Jana Slovácková and Vendula Pelková and Jirina Procházková and Karel Soucek and Petr Benes and Jan Smarda},

doi = {10.1515/BC.2009.007},

issn = {1431-6730},

year  = {2009},

date = {2009-01-01},

journal = {Biological chemistry},

volume = {390},

number = {1},

pages = {49–58},

abstract = {The Bcl-2 protein is one of the key components of biochemical pathways controlling programmed cell death. The function of this protein can be regulated by posttranslational modifications. Phosphorylation of Bcl-2 has been considered to be significantly associated with cell cycle arrest in the G2/M phase of the cell cycle, and with cell death caused by defects of microtubule dynamics. This study shows that phosphorylation of Bcl-2 can be induced by heavy metals due to activation of the Jun N-terminal kinase pathway that is not linked to the G2/M cell cycle arrest. Furthermore, we demonstrate that hyperphosphorylated Bcl-2 protein is a more potent inhibitor of zinc-induced cell death than its hypophosphorylated mutant form. These data suggest that regulation of Bcl-2 protein function by phosphorylation is an important part of cell responses to stress.},

note = {Place: Germany},

keywords = {Animals, Apoptosis/drug effects, Cell Line, Electrophoresis, Gene Expression Regulation, Heavy/*pharmacology, Humans, JNK Mitogen-Activated Protein Kinases/*metabolism, Metals, Neoplastic/drug effects, Phosphorylation/drug effects, Physiological/drug effects, Post-Translational/drug effects, Protein Processing, Proto-Oncogene Proteins c-bcl-2/*metabolism, Signal Transduction/drug effects, Stress, Tumor, Zinc/pharmacology},

pubstate = {published},

tppubtype = {article}

}

@article{gavelova_reduction_2008,

title = {Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.},

author = {Martina Gavelová and Jana Hladíková and Lenka Vildová and Romana Novotná and Jan Vondrácek and Pavel Krcmár and Miroslav Machala and Lenka Skálová},

doi = {10.1016/j.cbi.2008.07.011},

issn = {0009-2797},

year  = {2008},

date = {2008-10-01},

journal = {Chemico-biological interactions},

volume = {176},

number = {1},

pages = {9–18},

abstract = {In cancer cells, the drug-metabolizing enzymes may deactivate cytostatics, thus contributing to their survival. Moreover, the induction of these enzymes may also contribute to development of drug-resistance through acceleration of cytostatics deactivation. However, the principal metabolic pathways contributing to deactivation of many cytostatics still remain poorly defined. The main aims of the present study were: (i) to compare the reductive deactivation of cytostatic drugs doxorubicin (DOX) and oracin (ORC) in human breast cancer MCF-7 cells; (ii) to identify major enzyme(s) involved in the carbonyl reduction; and iii) to evaluate the activities and expression of selected carbonyl reducing enzymes in MCF-7 cells upon a short-term (48 h) exposure to either DOX or ORC. We found that MCF-7 cells were able to effectively metabolize both DOX and ORC through reduction of their carbonyl groups. The reduction of ORC was stereospecific, with a preferential formation of + enantiomer of dihydrooracin (DHO). The cytosolic carbonyl reductase CBR1 seemed to be a principal enzyme reducing both drugs, while cytosolic aldo-keto reductase AKR1C3 or microsomal reductases probably did not play important role in metabolism of either DOX or ORC. The exposure of MCF-7 cells to low (nanomolar) concentrations of DOX or ORC caused a significant elevation of reduction rates of both cytostatics, accompanied with an increase of CBR1 protein levels. Taken together, the present results seem to suggest that the accelerated metabolic deactivation of ORC or DOX might contribute to the survival of breast cancer cells during exposure to these cytostatics.},

note = {Place: Ireland},

keywords = {3-Hydroxysteroid Dehydrogenases/antagonists & inhibitors/genetics/metabolism, Alcohol Oxidoreductases/antagonists & inhibitors/*biosynthesis/genetics/metabolism, Aldehyde Reductase, Aldo-Keto Reductase Family 1 Member C3, Aldo-Keto Reductases, Biotransformation/drug effects, Blotting, Breast Neoplasms/*enzymology/genetics, Cell Line, Dose-Response Relationship, Doxorubicin/analogs & derivatives/chemistry/*metabolism/pharmacology, Drug, Enzyme Induction/drug effects, Enzyme Inhibitors/pharmacology, Ethanolamines/chemistry/*metabolism/pharmacology, Gene Expression Regulation, Humans, Hydroxyprostaglandin Dehydrogenases/antagonists & inhibitors/genetics/metabolism, Isoquinolines/chemistry/*metabolism/pharmacology, Kinetics, Messenger/genetics/metabolism, Methacrylates/pharmacology, Neoplastic/drug effects, Oxidation-Reduction/drug effects, Phenylpropionates/pharmacology, Quercetin/analogs & derivatives/pharmacology, RNA, Subcellular Fractions/drug effects/metabolism, Tumor, Western},

pubstate = {published},

tppubtype = {article}

}

@article{marvanova_toxic_2008,

title = {Toxic effects of methylated benz[a]anthracenes in liver cells.},

author = {Sona Marvanová and Jan Vondrácek and Katerrina Penccíková and Lenka Trilecová and Pavel Krcmárr and Jan Topinka and Zuzana Nováková and Alena Milcová and Miroslav Machala},

doi = {10.1021/tx700305x},

issn = {0893-228X},

year  = {2008},

date = {2008-02-01},

journal = {Chemical research in toxicology},

volume = {21},

number = {2},

pages = {503–512},

abstract = {Monomethylated benz[ a]anthracenes (MeBaAs) are an important group of methylated derivatives of polycyclic aromatic hydrocarbons (PAHs). Although the methyl substitution reportedly affects their mutagenicity and tumor-initiating activity, little is known about the impact of methylation on the effects associated with activation of the aryl hydrocarbon receptor (AhR)-dependent gene expression and/or toxic events associated with tumor promotion. In the present study, we studied the effects of a series of MeBaAs on the above-mentioned end points in rat liver cell lines and compared them with the effects of benz[ a]anthracene (BaA) and the potent carcinogen 7,12-dimethylbenz[ a]anthracene (DMBA). Methyl substitution enhanced the AhR-mediated activity of BaA derivatives determined in a reporter gene assay, as the induction equivalency factors (IEFs) of all MeBaAs were higher than that of BaA. IEFs of 6-MeBaA and 9-MeBaA, two of the most potent MeBaAs, were more than two orders of magnitude higher than the IEF of BaA. Correspondingly, all MeBaAs induced higher levels of cytochrome P450 1A1 mRNA. Both BaA and MeBaAs had similar effects on the expression of cytochrome P450 1B1 or aldo-keto reductase 1C9 in rat liver epithelial WB-F344 cells. In contrast to genotoxic DMBA, MeBaAs induced low DNA adduct formation. Only 10-MeBaA induced apoptosis and accumulation of phosphorylated p53, which could be associated with the induction of oxidative stress, similar to DMBA. With the exception of 10-MeBaA, all MeBaAs induced cell proliferation in contact-inhibited WB-F344 cells, which corresponded with their ability to activate AhR. 1-, 2-, 8-, 10-, 11-, and 12-MeBaA inhibited gap junctional intercellular communication (GJIC) in WB-F344 cells. This mode of action, like disruption of cell proliferation control, might contribute to tumor promotion. Taken together, these data showed that the methyl substitution significantly influences those effects of MeBaAs associated with AhR activation or GJIC inhibition.},

note = {Place: United States},

keywords = {10-Dimethyl-1, 2-benzanthracene/chemistry/metabolism/toxicity, 9, Animals, Apoptosis/drug effects, Benz(a)Anthracenes/chemistry/metabolism/*toxicity, Carcinoma, Cell Line, Cell Proliferation/drug effects, Cytochrome P-450 Enzyme System/genetics/metabolism, DNA Adducts/analysis/metabolism, DNA/drug effects/metabolism, Dose-Response Relationship, Drug, Enzyme Induction, Enzymologic/drug effects, Gap Junctions/drug effects, Gene Expression Regulation, Genes, Hepatocellular, Hepatocytes/*drug effects/metabolism/pathology, Inbred F344, Liver Neoplasms, Messenger/metabolism, Methylation, Rats, Reporter/drug effects, RNA, Stem Cells/*drug effects/metabolism/pathology, Tumor},

pubstate = {published},

tppubtype = {article}

}

@article{umannova_tumor_2007,

title = {Tumor necrosis factor-alpha modulates effects of aryl hydrocarbon receptor ligands on cell proliferation and expression of cytochrome P450 enzymes in rat liver "stem-like" cells.},

author = {Lenka Umannová and Jirina Zatloukalová and Miroslav Machala and Pavel Krcmár and Zuzana Májková and Bernhard Hennig and Alois Kozubík and Jan Vondrácek},

doi = {10.1093/toxsci/kfm149},

issn = {1096-6080 1096-0929},

year  = {2007},

date = {2007-09-01},

journal = {Toxicological sciences : an official journal of the Society of Toxicology},

volume = {99},

number = {1},

pages = {79–89},

abstract = {Various liver diseases lead to an extensive inflammatory response and release of a number of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha). This cytokine is known to play a major role in liver regeneration as well as in carcinogenesis. We investigated possible interactions of TNF-alpha with ligands of the aryl hydrocarbon receptor (AhR) and known liver carcinogens, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and coplanar 3,3',4,4',5-pentachlorobiphenyl (PCB 126). These compounds have been previously found to disrupt cell cycle control in contact-inhibited rat liver WB-F344 cells, an in vitro model of adult liver progenitor cells. TNF-alpha itself had no significant effect on the proliferation/apoptosis ratio in the WB-F344 cell line. However, it significantly potentiated proliferative effects of low picomolar range doses of both TCDD and PCB 126, leading to an increase in cell numbers, as well as an increased percentage of cells entering the S-phase of the cell cycle. The combination of TNF-alpha with low concentrations of AhR ligands increased both messenger RNA (mRNA) and protein levels of cyclin A, a principle cyclin involved in disruption of contact inhibition. TNF-alpha temporarily inhibited AhR-dependent induction of cytochrome P450 1A1 (CYP1A1). In contrast, TNF-alpha significantly enhanced induction of CYP1B1 at both mRNA and protein levels, by a mechanism, which was independent of nuclear factor-kappaB activation. These results suggest that TNF-alpha can significantly amplify effects of AhR ligands on deregulation of cell proliferation control, as well as on expression of CYP1B1, which is involved in metabolic activation of a number of mutagenic compounds.},

note = {Place: United States},

keywords = {Animals, Aryl Hydrocarbon Hydroxylases/genetics/*metabolism, Aryl Hydrocarbon/*drug effects/metabolism, Carcinogens/metabolism/toxicity, Cell Proliferation/drug effects, Cells, Cultured, Cytochrome P-450 CYP1A1/genetics/metabolism, Cytochrome P-450 CYP1B1, Dose-Response Relationship, Drug, Drug Combinations, Drug Interactions, Enzymologic/*drug effects, Epithelial Cells/drug effects/enzymology, Gene Expression Regulation, Inbred F344, Ligands, Liver/cytology, Polychlorinated Biphenyls/metabolism/*toxicity, Polychlorinated Dibenzodioxins/metabolism/*toxicity, Rats, Receptors, Stem Cells/*drug effects/enzymology, Tumor Necrosis Factor-alpha/*pharmacology},

pubstate = {published},

tppubtype = {article}

}